<DOC>
	<DOCNO>NCT01429519</DOCNO>
	<brief_summary>The study objective evaluate safety efficacy topical administration RPh201 oil solution ( botanical extract ) treatment patient hard heal chronic ulcerated wound .</brief_summary>
	<brief_title>Efficacy RPh201 Applied Topically Treatment Hard Heal Chronic Ulcerated Wounds</brief_title>
	<detailed_description>The study objective evaluate safety efficacy , topical administration RPh201 treatment patient hard heal wound . This include : - Safety evaluation RPh201 ( botanical extract ) formulate oil solution administer topically three time per week overall treatment period 4 week patient hard heal wound . - Efficacy assessment wound improvement follow use RPh201 oil solution ( botanical extract ) administer topically three time per week overall treatment period 4 week follow-up visit 3 month end treatment patient hard heal wound</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<criteria>1 . Participants , either men woman â‰¥ 18 year age . 2 . Patients must least one hard heal wound different etiology ( venous insufficiency , lymphatic insufficiency , neuropathic wound diabetic ulcer , post operative posttraumatic chronic wound ) locate leg shin foot . 3 . The wound refractive healing least 4 week prior treatment , although treat routine practice . 4 . Wound area size range : 3 36 square centimeter . 5 . Patients define grade C granulometer scale ( see section 6.5.1 ) . 6 . Participants understand nature procedure provide write informed consent prior study procedure . 7 . Women child bear potential must use adequate birthcontrol precaution . 1 . Clinically significant arterial vascular disease ABI index &lt; 0.45 peripheral pulse palpable , flatted PVR case non palpable artery . 2 . Clinical evidence presence infection soft tissue , joint and/or bone ( osteomyelitis ) . 3 . Wound Nonviable tissue cover 50 % wound area . 4 . Patients skin disorder unrelated ulcer present adjacent wound . 5 . The wound penetrate deep organ involve bone , tendon joint 6 . Wound sinus tract 7 . Patients receive , receive within one month prior enrollment treatment know impair wound healing , include limited : immunosuppressive drug , cytotoxic agent , radiation therapy chemotherapy . 8 . Treatment dress contain growth factor biological dressing within 15 day , prior screen visit . 9 . Patients history alcohol drug abuse within last two year . 10 . Female patient pregnant nursing , childbearing potential use adequate contraception . 11 . Participation another clinical trial within 30 day prior Screening Visit study . 12 . Clinically significant and/or uncontrolled condition significant medical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>chronic wound</keyword>
	<keyword>ulcerated wound</keyword>
	<keyword>venous insufficiency</keyword>
	<keyword>lymphatic insufficiency</keyword>
	<keyword>neuropathic wound</keyword>
	<keyword>diabetic ulcer</keyword>
	<keyword>post- operative</keyword>
	<keyword>post-traumatic chronic wound</keyword>
</DOC>